Navigation Links
NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Date:6/16/2011

SANTA CLARA, Calif., June 16, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that two of its recent medical and technical submissions have been accepted for their presentations at the 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society conference.  

The two papers: 'Wireless Monitoring of Reconstructed 12-Lead ECG in Atrial Fibrillation Patients Enables Differential Diagnosis of Recurrent Arrhythmias' and 'Algorithm for Quantitative 3-Dimensional Analysis of ECG Signals Improves Myocardial Diagnosis Over Cardiologists in Diabetic Patients', will be presented during the conference to be held September 1-4, in Boston, Mass.

NewCardio scientists and their academic medical collaborators will present data from recently completed clinical studies that highlight the diagnostic potentials of two company products, CardioBip™ and my3KG™:  

  • The first of these studies showed that CardioBip accurately captured, wirelessly transmitted, and reconstructed full 12-lead ECG data from patients with atrial fibrillation (AF) who had previously undergone a therapeutic catheter ablation procedure. Such patients are at significant risk for stroke from recurrent bouts of AF; moreover, currently available cardiac monitoring techniques all have significant limitations for recurrent AF detection that may be addressed by long-term CardioBip monitoring. The NewCardio-sponsored study showed that (1) post-ablation AF patients could conveniently monitor themselves for recurrent AF with CardioBip for the entire duration of the study (6 months); (2) CardioBip frequently detected AF recurrences, whether the patient had symptoms or not; and (3) CardioBip was substantially more sensitive and accurate that periodic sustained (12-lead 24 hours Holter) monitoring in detecting recurrent AF.  
  • The second study s
    '/>"/>

SOURCE NewCardio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Top 5 Global Pharmaceutical Company Selects NewCardios QTinno for 2 Upcoming Phase I Drug Safety Trials
2. NewCardio Joins the Cardiac Safety Research Consortium
3. Dorin Panescu Named NewCardios Chief Technical Officer
4. NewCardio Management to Host Conference Call on October 21
5. 22 of Americas Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences
6. Dr. Frank Fisher of Stevens selected for Fulbright specialist roster
7. SuperNova Diagnostics® Selected to Present at Launch: Silicon Valley 2011
8. Conflict of Interest Management System Selected by Henry Ford Health System
9. Honeywells Envergent Technologies Selected by Malaysian Company for Renewable Energy Project
10. RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
11. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma ... a recommended approach for protecting personal data in ... researchers, patients and others. The document describes an ... information from CSRs and other related clinical trial ... The goal of the TransCelerate CSR Redaction ...
(Date:9/2/2014)... September 02, 2014 Myriant Corporation, ... signage of a distribution agreement with Azelis Group, ... distributing Myriant’s bio-succinic acid in the Nordics, Benelux, ... targeting customers in the industrial and base chemicals ... Azelis offers a far-reaching chemical portfolio with extensive ...
(Date:9/2/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... (PTO) has issued a patent related to NB32, the ... is a fixed-dose combination of naltrexone sustained release (SR) ... claims methods for treating insulin resistance using a composition ... If NB32 is approved for use in ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... presented today show that RAPAFLO(R) (silodosin) significantly reduced ... pain syndrome (CP/CPPS).  In the study presented at ... RAPAFLO(R) also significantly improved urinary symptoms as well ... pelvic pain syndrome (CP/CPPS) is a common condition ...
... 2011 Brian Olson didn,t exactly fit the image of an ... first to admit it. "I had just a GED and was ... math." With a vague notion that he wanted to ... enrolled in basic chemistry and biology courses as a freshman. ...
... May 17, 2011 P f enex ... has submitted a Biologics Master File (BMF) to the United ... carrier protein to support the development of conjugate vaccine products ... supplying cGMP grade CRM197 carrier protein to multiple partners in ...
Cached Biology Technology:Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 2Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 3Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 5Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 6From GED to PhD: Borough of Manhattan Community College's Brian Olson Faces Academic Deficits Only to Be Rewarded with Acceptance to CUNY's PhD Program in Biochemistry 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3
(Date:9/2/2014)... lithographic limestone is well known as a result ... area (for example, Archaeopteryx). Now, for the first ... French equivalent of these outcrops - discoveries which ... water treader. , Despite the abundance of fossils ... been obtained from the Late Kimmeridgian equivalents of ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
(Date:9/1/2014)... U.S. has improved steadily in recent yearsspurred in large ... remains poor and disparities continue to widen among socioeconomic ... Harvard School of Public Health (HSPH). , "The study ... extensive efforts by many groups and individuals to improve ... also indicates that these efforts need to be expanded," ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... has identified a lung protein that appears to play ... an antibody to block its activity, Indiana University scientists ... the protein, a cytokine named EMAPII, could provide a ... M.D., associate professor of medicine at the Indiana University ...
... take to regenerate a limb? Biologists have long thought that ... cells that can generate any tissue in the body. But ... regrow the complete organ, at least in zebrafish. Researchers ... shown that cells capable of regenerating a zebrafish fin do ...
... has worked with wireless sensor network developers Senceive, ... across critical structures in the UK that will ... Senceive,s main application area is long-term infrastructure monitoring. ... used to assess the condition of railway structures, ...
Cached Biology News:Protein could offer target to reduce lung damage from smoking-caused emphysema 2Zebrafish regrow fins using multiple cell types, not identical stem cells 2NPL helps Senceive to offer improved monitoring of structural assets across the UK 2
... Monoclonal Mouse Antibody to Cytokeratin 5 / ... a high molecular weight, basic type of ... the superficial cell layers of stratified epithelia ... and in mesothelial cells and mesothelioma. Cytokeratin ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Biology Products: